Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) | MicrobiomeTrials
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-05-19Est. Completion: 2035-08-01
Enrollment target: 348 participants
Locations
Circuit Clinical, Orchard Park, New York, United States
Novartis Investigative Site, Vitória, Espírito Santo, Brazil
Novartis Investigative Site, Salvador, Estado de Bahia, Brazil
Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil
Novartis Investigative Site, Recife, Pernambuco, Brazil
Novartis Investigative Site, Santo André, São Paulo, Brazil
Novartis Investigative Site, Guangzhou, Guangdong, China
Novartis Investigative Site, Shantou, Guangdong, China
Novartis Investigative Site, Shenzhen, Guangdong, China
Novartis Investigative Site, Liuzhou, Guangxi, China
Novartis Investigative Site, Wuhan, Hubei, China
Novartis Investigative Site, Changchun, Jilin, China
Novartis Investigative Site, Shenyang, Liaoning, China
Novartis Investigative Site, Binzhou, Shandong, China
Novartis Investigative Site, Ningbo, Zhejiang, China
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Chongqing, China
Other microbiome trials you might be interested in